Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her ...

Broking analysts have lowered their expectations on Cochlear, but in the main their valuations are above the current share ...

PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

PYC is looking at therapies across retinitis pigmentosa, polycystic kidney disease, genetic condition Phelan McDermid syndrome, and autosomal dominant optic atrophy, with other undisclosed ...